1.
J Hosp Infect
; 112: 104-107, 2021 Jun.
Article
in English
| MEDLINE | ID: covidwho-1272537
ABSTRACT
Personal protective equipment (PPE) is essential for healthcare worker (HCW) safety. Conservation of PPE for clinical use during the COVID-19 pandemic reduced its availability for training, necessitating an innovative approach to sourcing high physical resemblance PPE (HPR-PPE). We present a case study of crowd-sourcing of HPR-PPE to train HCWs. Survey results indicated that HPR-PPE enabled high-fidelity practise of PPE application and removal, aided procedure recall, improved user confidence and was sufficiently similar to medical-grade PPE. HPR-PPE provided a novel and cost-effective alternative. We also demonstrated that medical-grade PPE can be sourced from non-medical institutions and businesses during a pandemic.
Subject(s)
COVID-19/prevention & control , Health Personnel/education , Infection Control/methods , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Personal Protective Equipment/supply & distribution , Case-Control Studies , Crowdsourcing , Durable Medical Equipment , Humans , Infection Control/instrumentation , Qualitative Research , Respiratory Protective Devices , Simulation Training
2.
ClinicalTrials.gov; 06/08/2020; TrialID: NCT04513158
Clinical Trial Register
| ICTRP | ID: ictrp-NCT04513158
ABSTRACT
Condition:
Covid19Intervention:
Biological: Convalescent PlasmaPrimary outcome:
Determine the therapeutic efficacy (response rate) of convalescent plasma infusion in patients at high risk for mortality when infected by SARS-CoV-2 (COVID-19).Criteria:
Inclusion Criteria:
- Diagnosis of SARS-CoV-2 infection via RT-PCR or FDA approved testing.
- Patients must also have the following indications for enrollment:
- i. D-Dimer > 500 ng/ml FEU OR
- ii. IL-6> 5 pg/mL
With any of the following:
- iii. Lymphocytes < 0.8 103/ul OR
- iv. LDH > 700 U/L OR
- v. CK > 170 U/L OR
- vi. CRP > 1.0 mg/dl OR
- vii. Ferritin > 1000 ng/ml
AND one of the following:
- viii. Age over 60 years
- ix. Underlying Active Malignancy
- x. Cardiovascular Disease
- xi. Active Tobacco Use
- xii. History of Pulmonary Volume Reduction Surgery
- xiii. Hypertension
- Prior Treatment: Patients are still eligible for this trial if active antimicrobial
agents are in use. Patients are also eligible if they had been treated on COVID-19
clinical trial in the course of their disease.
- Age = 18 years.
- The effects of allogeneic plasma infusion on the developing fetus is unknown. For this
reason women who are pregnant are not eligible to participate.
- Agrees to required laboratory data collected which will include the baseline organ
function and regular ongoing assessments done as part of routine care.
- Ability to understand and the willingness to sign a written informed consent document
or ability to have consent provided by Legally Authorized Representative.
Exclusion Criteria:
- 4.2.1 Patients who do not meet above inclusion criteria are not eligible.
- 4.2.2 Patients may not be receiving any other investigational agents.
- 4.2.3 History of allergic reactions attributed to previous transfusion history.
- 4.2.4 Respiratory rate >30/min
- 4.2.5 Blood oxygen saturation <93%
- 4.2.6 Partial pressure of arterial oxygen to fraction of inspired oxygen ration <300
- 4.2.7 Diagnosis of respiratory failure, septic shock or multiple organ
dysfunction/failure